Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDFE-2304 vs Minoxidil in Men with Androgenetic Alopecia
NCT07011485Phase 2Active, not recruiting
- Sponsor
- PDFE Pharma Innovations
- Start
- May 2025
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in androgenetic alopecia (AGA) (2 arms), sponsored by PDFE Pharma Innovations. Primary endpoint: Target Area Hair Count at Week 16. Started May 2025; status: active, not recruiting.
02
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07011485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011485.